Instalab
logoInstalab

Glycolic Acid

Urine Test
Get an early read on oxalate metabolism, the hidden driver behind many calcium kidney stones.
4.9 (2,951 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Glycolic Acid test?

This test is most useful if any of these apply to you.

Dealing With Recurring Kidney Stones
This test can show whether your stone-forming oxalate is being driven by an upstream metabolic source you can act on.
Family History of Hyperoxaluria
If a relative has had primary hyperoxaluria, this is one piece of a workup that catches the disease before stones or kidney failure appear.
Investigating Unexplained Kidney Decline
If your kidney numbers are slipping without a clear cause, this gives an exploratory look at organic acid pathways standard panels skip.
Curious About Hidden Metabolic Patterns
This is a research-level marker that adds nuance to a full metabolic workup, useful if you want a deeper picture than basic kidney labs offer.

About Glycolic Acid

If you have had a calcium oxalate kidney stone, your standard panel told you your oxalate level but not what produced it. Glycolic acid (also called glycolate) sits one step upstream of oxalate in your metabolism, offering a clue about where the oxalate is coming from.

This is not a routine test. It is used in three main situations: investigating rare metabolic kidney stone disorders, assessing exposure to certain toxic chemicals, and tracking emerging biomarker patterns in autoimmune kidney disease. Standardized cutpoints do not yet exist outside of these specific contexts, so a single reading should always be interpreted alongside oxalate and clinical history.

Calcium Oxalate Stones and Primary Hyperoxaluria

Primary hyperoxaluria type 1 (an inherited disorder that causes the body to overproduce oxalate) leads to severe stones and eventual kidney failure. Glycolic acid is part of that metabolic pathway, but research in a European hyperoxaluria cohort of 932 patients showed that urinary glycolate alone does not predict who will progress to kidney failure; in that study, urinary oxalate excretion, AGXT null variants, and nephrocalcinosis were the strongest determinants. Glycolate is elevated in only about two-thirds of people with primary hyperoxaluria type 1, so a normal level does not rule out the diagnosis either.

For people with no known genetic disorder but recurrent calcium oxalate stones, glycolate still matters. It is one of the main internal sources of the oxalate your body produces. A controlled feeding study in healthy adults found that dietary hydroxyproline (a protein building block found in collagen and gelatin) accounts for about 20 to 50 percent of urinary glycolate and 5 to 20 percent of the oxalate your body makes from scratch. Other amino acids, like glycine and phenylalanine, contribute only minor amounts at normal intake levels.

Ethylene Glycol and Toxic Alcohol Poisoning

Ethylene glycol, the active ingredient in antifreeze, is broken down in the body into glycolic acid and then oxalate. Both are highly toxic and cause severe kidney injury. Glycolic acid can be measured in either blood or urine. In a forensic study of fatal poisonings, blood glycolic acid concentrations near 1.5 grams per liter indicated fatal exposure, while urinary levels were typically much higher (around 5 grams per liter). A systematic review identified roughly 990 milligrams per liter in serum as a useful cutoff for predicting mortality in acute cases, and a more recent review found that a serum glycolate around 1,490 milligrams per liter best predicted mortality, with death unlikely below about 600 milligrams per liter.

In contrast, victims of diethylene glycol poisoning (a related industrial chemical found in some contaminated medications) showed low urinary glycolic acid, likely because acute kidney failure stopped them from excreting it. For a healthy reader, this explains why glycolate is part of forensic and toxicology testing, not why it would normally be ordered preventively.

Lupus Nephritis

A small single-center study in people with systemic lupus erythematosus (an autoimmune disease that often attacks the kidneys) found that urinary glycolic acid discriminated lupus involving the kidneys from lupus without kidney involvement with high accuracy, with an area under the curve of about 0.94 (where 1.0 would be perfect separation between the two groups). The work is preliminary, based on a small sample (17 patients without kidney damage and 23 with lupus nephritis), and has not yet been independently validated across other cohorts. It suggests potential as a noninvasive monitoring marker but should not be treated as established.

Diabetic Kidney Disease

A meta-analysis pooling clinical metabolomics studies of people with diabetic kidney disease and healthy controls identified glycolic acid as one of several key small molecules whose levels were significantly different in the disease group. The direction here is opposite to ethylene glycol poisoning: in diabetic kidney disease, glycolate tends to be lower, not higher. One smaller study found the opposite direction in patients with albuminuria, so the pattern may not be uniform across all subgroups. It appears as part of a broader pattern of disturbed amino acid and energy metabolism rather than as a standalone diagnostic test.

Why High Is Not Always Worse

Across the conditions where glycolic acid has been studied, the direction of abnormality goes both ways. Very high levels signal danger in ethylene glycol poisoning. Lower levels track with diabetic kidney disease. In a rare neurological disorder called succinic semialdehyde dehydrogenase deficiency, early metabolomics work has linked certain urinary metabolites to clinical severity, though the role of glycolic acid specifically is not yet well defined.

Glycolic acid is a phenotype indicator, not a universal good or bad number. The same value can mean very different things depending on context. This is why interpretation always requires the clinical setting and accompanying tests, especially urinary oxalate and kidney function markers.

When Results Can Be Misleading

  • Collagen-rich foods and supplements: gelatin, bone broth, and collagen peptides contain hydroxyproline, which your body converts to glycolate. In healthy adults, hydroxyproline ingestion raised urinary glycolate roughly 5-fold. Avoid these foods and supplements for 24 to 48 hours before collection.
  • Incomplete 24-hour collection: missing any urine during a 24-hour collection lowers the total reported value and can produce a falsely normal result. Start the collection by discarding the first morning void, then collect everything for the next 24 hours including the next morning's first void.
  • Severe kidney injury: in acute kidney failure, the kidneys may not filter glycolate effectively, so urinary levels can be paradoxically low even when blood levels are dangerously high. A low value during acute illness does not mean low production.
  • Lab method differences: glycolic acid can be measured by ion chromatography, gas chromatography mass spectrometry, or other techniques, and absolute numbers may not be directly comparable across labs. Use the same lab for serial tracking when possible.

Tracking Your Trend

A single reading is rarely conclusive. Glycolic acid shifts with diet, hydration, collection technique, and the lab method used. Get a baseline, then retest with standardized conditions, ideally at the same lab. If you are making dietary changes such as reducing collagen intake or adjusting protein sources, wait at least 4 to 6 weeks before retesting so the signal stabilizes. Annual tracking is reasonable for anyone with recurrent calcium oxalate stones or a family history of primary hyperoxaluria.

Decision Pathway for Unexpected Results

An isolated elevated glycolic acid is almost never enough to drive a clinical decision on its own. The first step is to pair it with urinary oxalate, since the two metabolites travel together in most relevant conditions. If both are elevated and you have a personal or family history of recurring stones, ask about evaluation for primary hyperoxaluria, which typically includes genetic testing of the AGXT, GRHPR, and HOGA1 genes (three genes responsible for the inherited forms of the disease).

If only glycolic acid is high and oxalate is normal, dietary review comes first. Collagen supplements, gelatin-heavy diets, and certain commercial protein products can drive the number up without causing kidney damage. If the elevation is persistent and unexplained after dietary changes, a referral to a nephrologist or metabolic specialist is appropriate. A normal result does not rule out primary hyperoxaluria, so clinical suspicion based on stone history still matters more than this one test.

What Moves This Biomarker

Evidence-backed interventions that affect your Glycolic Acid level

Increase
Eat collagen-rich foods such as gelatin, bone broth, or collagen peptide supplements
Foods rich in hydroxyproline (a building block of collagen) raise urinary glycolate roughly 5-fold and increase urinary oxalate by about 43 percent in healthy adults. If you are prone to calcium oxalate kidney stones, regular collagen supplementation can quietly feed the metabolic pathway that produces stone-forming oxalate, so it is worth knowing your baseline before adding it to your routine.
DietStrong Evidence
Increase
Take lumasiran (Oxlumo) for primary hyperoxaluria type 1
Lumasiran is an FDA-approved treatment for primary hyperoxaluria type 1 that works by silencing the gene for glycolate oxidase, the enzyme in the oxalate production pathway. By design, the drug raises urinary glycolate as it sharply reduces urinary oxalate. Phase 3 trial data show roughly a 65 percent reduction in 24-hour urinary oxalate over six months, with rising glycolate as a marker that the drug is working. The increase in glycolate itself is not harmful in this context.
MedicationStrong Evidence

Frequently Asked Questions

References

21 studies
  1. Elisabeth L. Metry, Sander F. Garrelfs, Lisa J. Deesker, C. Acquaviva, V. D'ambrosio, J. Bacchetta, Bodo B. Beck, P. Cochat, L. Collard, J. Hogan, P. M. Ferraro, C. Franssen, J. Harambat, S. Hulton, G. Lipkin, G. Mandrile, Cristina Martín-higueras, N. Mohebbi, S. Moochhala, T. Neuhaus, L. Prikhodina, E. Salido, R. Topaloğlu, M. Oosterveld, J. Groothoff, H. Peters-sengersKidney International Reports2023
  2. J. Knight, J. Jiang, D. Assimos, R. HolmesKidney International2006
  3. J. Knight, D. Assimos, M. Callahan, R. HolmesMetabolism: Clinical and Experimental2011
  4. J. Viinamäki, a. Sajantila, I. OjanperäJournal of Analytical Toxicology2015
  5. G. Tuero, J. González, Laura Sahuquillo, a. Freixa, I. Gomila, M. Elorza, B. BarcelóForensic Science International2018